AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20851843 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Δ9‐tetrahydrocannabinol (THC) 2.5 mg
Number of subjects: 9
Study 20851843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 20851843 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Δ9‐tetrahydrocannabinol (THC)
Number of subjects: 9
Study 19820488 — intervention group
Group type: COMPARATOR
Intervention: Colclean and EasyCT (group 1)
Number of subjects: 69
Study 19820488 — intervention group
Group type: COMPARATOR
Intervention: Colclean and Tagitol V (group 2)
Number of subjects: 69
Study 19820488 — intervention group
Group type: COMPARATOR
Intervention: LoSoPrep and EasyCT (group 3)
Number of subjects: 69
Study 19820488 — intervention group
Group type: EXPERIMENTAL
Intervention: LoSoPrep and Tagitol V (group 4)
Number of subjects: 69
Study 19820488 — intervention group
Group type: COMPARATOR
Intervention: Thick barium (Tagitol V)
Number of subjects: 69
Study 17384438 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (30 mg/d)
Number of subjects: 4133
Study 17384438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4133
Study 15054171 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV type specific serology testing
Number of subjects: 886
Study 15054171 — intervention group
Group type: COMPARATOR
Intervention: Control group (sex matched clinic attendees)
Number of subjects: 886
Study 11479396 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-dihydroergocryptine (DHEC)
Number of subjects: 12
Study 11479396 — intervention group
Group type: COMPARATOR
Intervention: L-Dopa alone
Number of subjects: 12
Study 9692099 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 0.2 mg once daily
Number of subjects: 76
Study 9692099 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 0.1 mg twice daily
Number of subjects: 76
Study 9692099 — intervention group
Group type: EXPERIMENTAL
Intervention: Washout period
Number of subjects: 76
Study 7921860 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous plasma transfusion
Number of subjects: 16
Study 7921860 — intervention group
Group type: COMPARATOR
Intervention: No autologous plasma transfusion
Number of subjects: 16
Study 2898209 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (0.25 to 4.0 micrograms/kg/min)
Number of subjects: 12
Study 2898209 — intervention group
Group type: COMPARATOR
Intervention: Saline-placebo control
Number of subjects: 12
Study 31959386 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion at 0.025 μg kg‐1 min‐1 (Group N1)
Number of subjects: 80
Study 31959386 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion at 0.05 μg kg‐1 min‐1 (Group N2)
Number of subjects: 80
Study 31959386 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion at 0.075 μg kg‐1 min‐1 (Group N3)
Number of subjects: 80
Study 31959386 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion at 0.10 μg kg‐1 min‐1 (Group N4)
Number of subjects: 80
Study 31959386 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Number of subjects: 80
Study 30916005 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation education plus a didactic session on speaking up behaviour (SE+)
Number of subjects: 22
Study 30916005 — intervention group
Group type: COMPARATOR
Intervention: Simulation education (SE)
Number of subjects: 22
Study 30916005 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SE and SE+)
Number of subjects: 22
Study 28090679 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride (2 mg/day)
Number of subjects: 24
Study 28090679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25204974 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (MSCs) treatment
Number of subjects: 20
Study 25204974 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 23950861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer warning (text only)
Number of subjects: 386
Study 23950861 — intervention group
Group type: EXPERIMENTAL
Intervention: Addiction warning (text only)
Number of subjects: 386
Study 23950861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer warning (text plus image)
Number of subjects: 386
Study 23950861 — intervention group
Group type: EXPERIMENTAL
Intervention: Addiction warning (text plus image)
Number of subjects: 386
Study 20739419 — intervention group
Group type: COMPARATOR
Intervention: 1 g encapsulated soybean oil/d plus 14.7 g liquid soybean oil/d (control group)
Number of subjects: 252
Study 20739419 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g encapsulated EPA/d plus 14.7 g liquid soybean oil/d (EPA group)
Number of subjects: 252
Study 20739419 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g encapsulated soybean oil/d plus 14.7 g liquid SDA-enriched soybean oil/d (SDA group)
Number of subjects: 252
Study 19202741 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (200 mg of faropenem)
Number of subjects: 12
Study 19202741 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (200 mg of faropenem)
Number of subjects: 12
Study 16901614 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic cardioversion (MP) with cumulative energy (CE) >150J
Number of subjects: 141
Study 16901614 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic cardioversion (MP) with cumulative energy (CE) <150J
Number of subjects: 141
Study 16901614 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic cardioversion (BP) with cumulative energy (CE) >150J
Number of subjects: 141
Study 16901614 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic cardioversion (BP) with cumulative energy (CE) <150J
Number of subjects: 141
Study 16901614 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MP and BP)
Number of subjects: 141
Study 12801490 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditionally prepared homeopathic A. nitricum 12X
Number of subjects: 62
Study 12801490 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionically-prepared A. nitricum 12X
Number of subjects: 62
Study 12801490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 10907676 — intervention group
Group type: EXPERIMENTAL
Intervention: Berocca
Number of subjects: 80
Study 10907676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 8654327 — intervention group
Group type: EXPERIMENTAL
Intervention: Method A (extensive quantitative food frequency questionnaire)
Number of subjects: 206
Study 8654327 — intervention group
Group type: EXPERIMENTAL
Intervention: Method B (shorter quantitative food frequency questionnaire with a 14 day food record)
Number of subjects: 206
Study 8654327 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined food record with a quantitative food frequency questionnaire
Number of subjects: 206
Study 1509971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 22
Study 1509971 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone
Number of subjects: 22
Study 1509971 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 22
Study 1509971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 6402959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn 40 mg
Number of subjects: 8
Study 6402959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30832542 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine cochlear implant evaluation
Number of subjects: 13
Study 29902464 — intervention group
Group type: EXPERIMENTAL
Intervention: Videos of black standardized patients (SPs)
Number of subjects: 113
Study 29902464 — intervention group
Group type: COMPARATOR
Intervention: Videos of white standardized patients (SPs)
Number of subjects: 113
Study 29902464 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon race (white versus other)
Number of subjects: 113
Study 29902464 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient race
Number of subjects: 113
Study 26799064 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIMAS (RCT)
Number of subjects: 254
Study 26799064 — intervention group
Group type: COMPARATOR
Intervention: PRIMAS (Implementation Trial)
Number of subjects: 254
Study 24634330 — intervention group
Group type: EXPERIMENTAL
Intervention: cHD with local citrate
Number of subjects: 23
Study 24634330 — intervention group
Group type: EXPERIMENTAL
Intervention: cHD with tinzaparin
Number of subjects: 23
Study 24634330 — intervention group
Group type: EXPERIMENTAL
Intervention: cHD using high-flux filter
Number of subjects: 23
Study 24634330 — intervention group
Group type: COMPARATOR
Intervention: cHD using low-flux filter
Number of subjects: 23
Study 24634330 — intervention group
Group type: COMPARATOR
Intervention: cHD patients
Number of subjects: 23
Study 22582483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous intralipid 10% infusion (10 cc/kg)
Number of subjects: 30
Study 22582483 — intervention group
Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 30
Study 19825502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive computer-assisted cognitive rehabilitation of attention, information processing and executive functions for 3 months
Number of subjects: 150
Study 19825502 — intervention group
Group type: COMPARATOR
Intervention: No rehabilitation (Control Group)
Number of subjects: 150
Study 17851140 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg sildenafil
Number of subjects: 14
Study 17851140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16109827 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (21-79 years)
Number of subjects: 58
Study 12134253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum nevirapine (200 mg to mother and 2 mg/kg to infant)
Number of subjects: 312
Study 12134253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 10192340 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy (arm 1): 180 cGy per fraction, total dose 5400 cGy, plus 100 mg/m2 infusional cisplatin.
Number of subjects: 130
Study 10192340 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated radiotherapy (arm 2): 117 cGy per fraction, total dose 7020 cGy, plus 100 mg/m2 infusional cisplatin.
Number of subjects: 130
Study 10192340 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (arm 1 and arm 2)
Number of subjects: 130
Study 8584992 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (targeted International Normalized Ratio 2.0 to 3.0) for a further eight weeks
Number of subjects: 301
Study 8584992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 8584992 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin for a further eight weeks
Number of subjects: 301
Study 8584992 — intervention group
Group type: EXPERIMENTAL
Intervention: Three months of warfarin
Number of subjects: 301
Study 2255932 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (2.5 and 5 micrograms/kilogram body weight)
Number of subjects: 0
Study 2255932 — intervention group
Group type: COMPARATOR
Intervention: Pethidine (0.8 milligram/kilogram)
Number of subjects: 0
Study 7378240 — intervention group
Group type: EXPERIMENTAL
Intervention: pancuronium
Number of subjects: 50
Study 7378240 — intervention group
Group type: EXPERIMENTAL
Intervention: tubocuraine
Number of subjects: 50
Study 7378240 — intervention group
Group type: EXPERIMENTAL
Intervention: alcuronium
Number of subjects: 50
Study 7378240 — intervention group
Group type: EXPERIMENTAL
Intervention: fazadinium
Number of subjects: 50
Study 7378240 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium
Number of subjects: 50
Study 31551228 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone combined with ambroxol hydrochloride
Number of subjects: 86
Study 31551228 — intervention group
Group type: COMPARATOR
Intervention: Ambroxol hydrochloride
Number of subjects: 86
Study 28224234 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day nasogastric tube decompression (NGT group)
Number of subjects: 233
Study 28224234 — intervention group
Group type: COMPARATOR
Intervention: no nasogastric tube decompression (no-NGT group)
Number of subjects: 233
Study 26571827 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast neutrons 6.3 MeV combined with neutron-photon therapy
Number of subjects: 0
Study 23897424 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-μg epinephrine test dose
Number of subjects: 24
Study 23897424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23897424 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold increase of 20 bpm
Number of subjects: 24
Study 23897424 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold increase of 10 bpm or increase in systolic blood pressure of 15 mm Hg or greater
Number of subjects: 24
Study 21768280 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified lipopolysaccharide (LPS)
Number of subjects: 0
Study 21768280 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS homologous to that expressed on the bactericidal test strain
Number of subjects: 0
Study 21768280 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous LPS
Number of subjects: 0
Study 21768280 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent-phase serum with CMP-NANA
Number of subjects: 0
Study 21768280 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly sialylated LPS
Number of subjects: 0
Study 19555710 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-factorial lifestyle intervention (including low intensity alcohol intervention)
Number of subjects: 9415
Study 19555710 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-factorial lifestyle intervention
Number of subjects: 9415
Study 19555710 — intervention group
Group type: COMPARATOR
Intervention: Control group (questionnaires)
Number of subjects: 9415
Study 16467444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 60
Study 16467444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 60
Study 12942477 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft inflow modification (GIM) by splenic artery ligation in G2, n = 13
Number of subjects: 24
Study 12942477 — intervention group
Group type: COMPARATOR
Intervention: No graft inflow modification in G1, n = 11
Number of subjects: 24
Study 11068838 — intervention group
Group type: EXPERIMENTAL
Intervention: lodixanol
Number of subjects: 160
Study 11068838 — intervention group
Group type: COMPARATOR
Intervention: lopromide
Number of subjects: 160
Study 9357205 — intervention group
Group type: COMPARATOR
Intervention: Metered Dose Inhaler with Spacer (Group II)
Number of subjects: 60
Study 9357205 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet Nebulizer (Group I)
Number of subjects: 60
Study 9357205 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group I and Group II)
Number of subjects: 60
Study 8442971 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 0.6 mg/kg
Number of subjects: 75
Study 8442971 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 0.3 mg/kg
Number of subjects: 75
Study 8442971 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study 2943613 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based benzoyl peroxide (Basiron)
Number of subjects: 48
Study 2943613 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-based benzoyl peroxide (Panoxyl)
Number of subjects: 48
Study 31278470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous sterile water injection (ISWI)
Number of subjects: 524
Study 31278470 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium injection
Number of subjects: 524
Study 29435760 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐Paced (S‐P) training
Number of subjects: 24
Study 29435760 — intervention group
Group type: COMPARATOR
Intervention: Standardised (STND) training
Number of subjects: 24
Study 27606699 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 162
Study 27606699 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE)
Number of subjects: 162
Study 27606699 — intervention group
Group type: COMPARATOR
Intervention: Minimal Attention Waitlist (WL)
Number of subjects: 162
Study 24486592 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 10% w/w freeze-dried black raspberry gel (BRB), 0.5 g × q.i.d., for 12 weeks
Number of subjects: 40
Study 24486592 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (identical formulation devoid of BRB)
Number of subjects: 40
Study 22395584 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2% and tretinoin 0.025% combination gel
Number of subjects: 79
Study 22395584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 20856131 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention (education on physical activity)
Number of subjects: 501
Study 20856131 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 501
Study 20071811 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine with adrenaline + 4 mg Dexamethasone (Group C)
Number of subjects: 90
Study 20071811 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine with adrenaline + 500 microg Neostigmine (Group B)
Number of subjects: 90
Study 20071811 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine with adrenaline (Group A)
Number of subjects: 90
Study 16871922 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride (BKC) 0.01% in saline nasal spray
Number of subjects: 43
Study 16871922 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free saline
Number of subjects: 43
Study 15596923 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) eligible patients (RPA class 3)
Number of subjects: 509
Study 15596923 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) eligible patients (RPA class 4)
Number of subjects: 509
Study 15596923 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS) ineligible patients (RPA class 4)
Number of subjects: 509
Study 15596923 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) eligible patients (RPA class 5)
Number of subjects: 509
Study 15596923 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS) ineligible patients (RPA class 5)
Number of subjects: 509
Study 15596923 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) eligible patients (RPA class 6)
Number of subjects: 509
Study 15596923 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS) ineligible patients (RPA class 6)
Number of subjects: 509
Study 11706096 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg daily for 1 week, then 300 mg daily for 5 weeks)
Number of subjects: 41
Study 11706096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 9282701 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (prescription and verbal instructions)
Number of subjects: 90
Study 9282701 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (prescription, syringe, and demonstration)
Number of subjects: 90
Study 9282701 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (prescription, syringe with marked line, and demonstration)
Number of subjects: 90
Study 9282701 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up demonstration
Number of subjects: 90
Study 7942479 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone treatment for 3 to 6 months (n = 11)
Number of subjects: 34
Study 7942479 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone treatment for > 1 year (n = 13)
Number of subjects: 34
Study 7942479 — intervention group
Group type: COMPARATOR
Intervention: Baseline (n = 10)
Number of subjects: 34
Study 3662543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS)
Number of subjects: 45
Study 3662543 — intervention group
Group type: COMPARATOR
Intervention: Cis-dichlorodiammineplatinum (CDDP) alone
Number of subjects: 45
Study 31155682 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) for 12 weeks
Number of subjects: 178
Study 31155682 — intervention group
Group type: COMPARATOR
Intervention: PFMT-solifenacin for 36 weeks
Number of subjects: 178
Study 31155682 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 178
Study 31155682 — intervention group
Group type: COMPARATOR
Intervention: PFMT-solifenacin
Number of subjects: 178
Study 30159716 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranked feedback
Number of subjects: 7846
Study 30159716 — intervention group
Group type: COMPARATOR
Intervention: Control (no feedback)
Number of subjects: 7846
Study 30159716 — intervention group
Group type: EXPERIMENTAL
Intervention: Benchmarked feedback
Number of subjects: 7846
Study 30159716 — intervention group
Group type: COMPARATOR
Intervention: Control vs Benchmarked
Number of subjects: 7846
Study 30159716 — intervention group
Group type: COMPARATOR
Intervention: Control vs Ranked
Number of subjects: 7846
Study 26918891 — intervention group
Group type: EXPERIMENTAL
Intervention: S. mansoni
Number of subjects: 2316
Study 26918891 — intervention group
Group type: EXPERIMENTAL
Intervention: T. trichiura
Number of subjects: 2316
Study 26918891 — intervention group
Group type: EXPERIMENTAL
Intervention: M. perstans
Number of subjects: 2316
Study 26918891 — intervention group
Group type: EXPERIMENTAL
Intervention: A. lumbricoides
Number of subjects: 2316
Study 25392260 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise protocol
Number of subjects: 35
Study 25392260 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical difference for sal‐T
Number of subjects: 35
Study 25392260 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical difference for sal‐C
Number of subjects: 35
Study 23547078 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab purging (P+; 375 mg/m(2) once per week for 4 weeks)
Number of subjects: 280
Study 23547078 — intervention group
Group type: COMPARATOR
Intervention: Observation (NP) before HDC-ASCT
Number of subjects: 280
Study 23547078 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance rituximab (M+; 375 mg/m(2) once every 2 months for four infusions)
Number of subjects: 280